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Graft survival following pancreas transplant alone (PTA) is inferior to other pancreas 
transplants. Steroid elimination is appealing, but a two drug maintenance strategy may be 
inadequate. Additionally, recipients tend to have diabetic nephropathy and do not tolerate 
nephrotoxic medications. A three-drug maintenance strategy permits immunosuppression 
through different mechanisms as well as an opportunity to use lower doses of the individual 
medications. Induction consisted of five doses of rabbit antithymocyte globulin (1 
mg/kg/dose). As of October 2007, a single dose of rituximab (150 mg/m2) was added. 
Maintenance consisted of tacrolimus, sirolimus  and mycophenolate mofetil. From 2004 to 
2017, 166 PTA were performed. Graft loss at 7- and 90- days were 4% and 5%, and one year 
patient and graft survival were 97% and 91%. Comparing induction without and with 
rituximab, there was no significant difference in 7 or 90 day graft loss, 1 year patient or graft 
survival or in the rate of rejection or infection. Rabbit antithymocyte globulin induction and 
steroid withdrawal followed by a three drug immunosuppression regimen is an excellent 
strategy for PTA recipients.  
 
Introduction: Pancreas transplantation has the potential to render candidates with Type 1 
diabetes euglycemic without the requirement for administration of exogenous insulin. This 
procedure requires a major abdominal operation and a lifelong commitment to 
immunosuppression, so it is currently exclusively offered as a treatment option to diabetics 
that require another extrapancreatic transplant, usually a kidney transplant for end stage 
diabetic nephropathy, or for patients with potentially life threatening complications of 
diabetes such as hypoglycemia unawareness. Historically, graft survival following pancreas 
transplant alone (PTA) has been inferior to that of other pancreas transplants due to a higher 
incidence of chronic rejection and late allograft failure[1]. This may be related to the fact that 
candidates for PTA tend to be younger than those presenting for a kidney and a pancreas. We 
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have previously reviewed the impact of age on pancreas transplant outcomes and have 
demonstrated inferior outcomes in the youngest population which we attributed to a more 
virulent immune system or to a greater frequency of noncompliance in the younger 
recipients[2]. Alternatively, the development of renal failure may also have an important 
impact on the immune system making chronic rejection less likely in recipients requiring 
both organs.  
Steroid elimination is very appealing in the setting of pancreas transplantation because of 
their extensive side-effect profile and poor tolerability [3-6]. In particular, for pancreas 
transplantation, concerns about insulin resistance and development of type II diabetes 
mellitus related to steroid therapy have been raised. This was one of the essential components 
of the Edmonton immunosuppression protocol for Islet transplantation[7] and has been well 
described in pancreas transplantation [8-10]. That being said, a two-drug maintenance 
strategy may be inadequate for PTA. Additionally, although not enough to qualify for kidney 
transplantation, recipients tend to have some degree of diabetic nephropathy and do not 
tolerate nephrotoxic medications at full dose. This patient population tends to also consist of 
particularly brittle diabetics where gastroparesis and other diabetes related bowel motility 
disorders may be quite common. For this reason, full dose mycophenolate mofetil or 
mycophenolic acid may not be tolerated. A three-drug maintenance strategy permits the 
simultaneous increase in overall immunosuppression while using lower doses of the 
individual medications in order to avoid toxicity. 
 There have been several reports associating development of donor specific antibody 
(DSA) with late allograft failure[11, 12]. We have previously reported our liver transplant 
immunosuppression protocol that included delayed rabbit antithymocyte globulin (rATG) (48 
hour delay, three doses for total of 6 mg/kg) and a single dose of rituximab (1.5 mg/m2)[13]. 
Based on this protocol rituximab was added for all PTA as well in an attempt to decrease 
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development of DSA and hopefully decrease longterm allograft loss to chronic rejection. We 
have previously reported the impact this has had on development of DSA in this patient 
population.[14] 
 This study is a retrospective single center analysis that describes the results using a 
steroid free rATG induction protocol with three drug immunosuppression maintenance 
therapy and comparing prior to and following introduction of rituximab as a component of 
induction.  
 
Materials and Methods: The medical records for all adult, deceased donor PTA transplants 
performed at Indiana University between January 2004 and September2017 were reviewed 
(n=166). Data were extracted from the comprehensive transplant recipient registry 
maintained at our center, individual written and electronic medical records, and the original 
donor medical history.  Inclusion criteria for this analysis included all PTA recipients. 
Pancreas retransplants, even if performed early, were included in this analysis.  
All recipients were listed for transplantation at Indiana University according to 
standard procedures and protocols as established by our own center and the United Network 
for Organ Sharing (UNOS). During the study period, in order to qualify for pancreas 
transplant listing at our institution, the potential recipient had to be insulin dependent with a 
fasting serum C-peptide level < 2 ng/ml. For PTA, the recipients had to demonstrate 
preserved renal function, usually with a creatinine clearance of at least 50 ml/min/1.73m2 . 
Pancreas allografts were typically procured using an en-bloc technique following 
aortic flush with preservation solution and topical cooling with saline slush as previously 
described [15, 16]. The recipient operation was performed through a midline incision. The 
pancreas was routinely positioned with the tail toward the pelvis and the head and duodenum 
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oriented superiorly in order to facilitate the enteric anastomosis. Systemic venous drainage 
was performed to the vena cava or to the right common iliac vein. Arterial perfusion of the 
allograft was routinely established from the right common iliac artery, although on rare 
occasions where this vessel was found to be diseased or had been the site for arterial 
anastomosis for a prior transplant, the inflow would be established either from the aorta or the 
left common iliac artery. All pancreas allografts were drained enterically using a stapled 
technique as described elsewhere [17].  
The induction immunosuppression protocol consisted of five doses of rATG  (1 
mg/kg/dose) and maintenance (initiated post-operative day 1)with tacrolimus (target trough 
6-8 ng/ml), sirolimus (target trough 3-6 ng/ml) and mycophenolate mofetil (MMF)  (500 mg 
po bid)[8, 18]. Steroids were exclusively used as a premedication for rATG and were 
discontinued following induction in all recipients. As of October 2007, due to the higher 
incidence of chronic immunologic graft loss in the PTA population, we have also added a 
single dose of rituximab (150 mg/m2) as well on post-operative day #1. In certain situations 
where the side effects of the maintenance immunosuppression were not well tolerated, MMF 
was replaced with either mycophenolic acid or azathioprine. In some instances where only 
two of the three maintenance immunosuppression medications were tolerated, a monthly 
infusion of basiliximab was added to the maintenance immunosuppression regimen. All 
recipients received routine perioperative antibiotics, prophylaxis against cytomegalovirus 
(CMV) with oral valgancyclovir and prophylaxis against Pneumocystis jiroveci pneumonia 
with trimethoprim and sulfamethoxazole, unless contraindicated. Systemic anticoagulation 
was not routinely used unless the patient had a specific history of a coagulation disorder.  
Primary transplant outcomes included 7-day and 90-day pancreas allograft loss and 1- 
year pancreas allograft and patient survival. Pancreas allograft failure was defined by 
dependence on subcutaneous insulin administration. All occurrences and causes of graft loss 
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or patient death were included in the final analysis. Demographic data were compared using 
standard chi-square and analysis of variance (ANOVA) testing. Retrospective review of data 
from the transplant center database was approved by the institutional review board of the 
Indiana University School of Medicine. 
Results: From 2004 to 2017, 166 PTA were performed. Donor and recipient demographics 
are presented in Table 1. The median follow-up for the entire population was 80 months. 6% 
of cases were retransplants. 31% of donor recipient combinations were CMV positive to 
negative (high risk). A prior diagnosis of gastroparesis was noted for 20% of the recipients. 
Outcomes for the entire PTA patient population are presented in Table 2. Median length of 
stay was 7 days and readmissions within the first 3 months was 49% of which 29% were 
related to dysmotility and dehydration. Specifically, graft loss at 7 and 90 days were 4% and 
5% respectively and one-year patient and pancreas allograft survival were 97% and 91% 
respectively. The majority of patients tolerated a three drug maintenance regimen with 
calcineurin inhibitor, sirolimus and either mycophenolate mofetil, mcophenolic acid or 
azathioprine with only 25 patients (15%) requiring monthly infusion of basiliximab as a third 
agent. Within the first year, the Incidence of infection was 43% (CMV 11%). There were 31 
patients treated for rejection (19%), all of which were treated with bolus steroids and with 22 
also receiving rATG treatment. 11 patients were treated more than once for rejection. Five-
year pancreas allograft survival was 68%. Median fasting c-peptide was 2.0 ng/ml with a 
median HBA1C of 5.5%. In terms of renal function, the median glomerular filtration rate 
(GFR) prior to transplant was 90 ml/min/1.73m2 with a range from 97 to 42 ml/min/1.73m2. 
However, many of patients were reported as GFR>90 ml/min/1.73m2, so we do not know 
precisely what the upper limit is.  There were only 3 patients with GFR < 50 ml/min/1.73m2  
and 17 patients with GFR < 60 ml/min/1.73m2. At one year post-transplant, the median GFR 
had decreased to 79 ml/min/1.73m2. In terms of body weight, this remained reasonably stable 
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with a change from baseline of -2.8 KG. Overall, throughout the entire study period, there 
were 17 deaths: Three were related to postoperative complications (1 leak, 2 aspiration 
pneumoniae), one from graft versus host disease, one suicide, two accidental deaths (motor 
vehicle accident and air embolus), two from malignancy (acute myelogenous leukemia and 
metastic squamous cell lung cancer), three cardiac deaths, two late deaths (renal failure with 
septic shock and gastrointestinal hemorrhage) and three deaths of unknown cause. Fourteen 
of these patients died with functioning pancreas allografts. 
 
Comparing induction without (35 (21%), median follow-up 141 months) to with (131 (79%), 
median follow-up 62 months) rituximab, there was no significant difference in recipient 
demographics, although there were significantly more female donors (p=0.04) in the 
rituximab group (Table 1). Median length of stay was similar at 7 days for both groups. 
Readmissions within the first 3 months were similar (50% and 49%, for with and without 
rituximab, respectively) with 26% and 40% being related to dysmotility and dehydraton. 
There was no significant difference in 7-day (3% vs 6%) or 90-day (5% vs 6%) graft loss, 1 
year patient (97% in both) or graft (92% vs 86%, p=0.22) survival. Median HBA1C were 
similar (5.5% vs 5.4%) as was median fasting c-peptide levels (2.0 ng/ml in both). The 
median GFR at baseline was 90 ml/min/1.73m2  in both groups and decreased to 76 and 84 
ml/min/1.73m2  at one year. In terms of body weight, this remained reasonably stable and was 
similar between the groups (-1.3 kg and -3.9 kg). There was also no difference in first year 
rate of rejection (7% vs 6%, p=1) or infection (41% vs 51%, p=0.24) (Table 2). First year 
CMV rates were also comparable at 12%vs 9%, (p=0.65) with more recipients in the high 
risk donor positive to recipient negative in the rituxan group (33% vs 26%). ten-year allograft 
and patient survival comparing with and without rituximab are shown in Figures 1 and 2. The 
differences were not significant (p=0.65 , 0.19). As the majority of deaths were with a 
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functioning pancreas allograft (14/17), we have also included death censored pancreas 
allograft survival which did not reach significance but did demonstrate further splaying of the 
survival curves favoring the group that received ritximab (p=0.17). 
Discussion:  
Of all the different varieties of pancreas transplantation, PTA remains the most problematic 
for several reasons. First, the allograft survival is inferior to all other combinations of 
pancreas transplantation, including pancreas after kidney transplantation which is also an 
isolated pancreas allograft. This inferior graft survival is the result of increased early graft 
loss from technical issues, mostly allograft thrombosis, and from a high rate of late attrition 
from chronic rejection. Second, the patient population is complicated. Typically, patients 
present at a younger age compared to recipients that also require a renal transplant. They tend 
to be more brittle and have a higher incidence of gastrointestinal issues such as gastroparesis 
and diabetic bowel motility disorders. Finally, although their kidney function has not 
deteriorated enough to mandate renal transplantation, these patients’ kidneys have been 
exposed to years of diabetes and the function is typically somewhat impaired. Although less 
common, this patient population also includes patients that have previously undergone total 
pancreatectomy for non-malignant diseases, which can represent a very difficult reoperative 
pancreas transplantation. With all of these factors combined, although the operation sounds 
straightforward, this is a physiologically and immunologically complicated recipient 
population. 
The strategy for immunosuppression described here was developed in order to provide 
increased immunosuppression by combining three non-steroid agents in order to decrease 
pancreas allograft attrition to chronic rejection and to minimize individual medication dosing 
in order to decrease toxicity. Similar approaches applying the same philosophy (although 
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including corticosteroids) have been independently reported[19]. In terms of efficacy, the 
pancreas allograft short and long term survival is superior to that reported from the Organ 
Procurement and Transplantation Network/ Scientific Registry of Transplant Recipients 
(OPTN/SRTR) with 1 year survival of 74.5% and 5 year survival at 50.6%[1] and that of the 
International Pancreas Transplant Registry (83% 1 year and 65.5% 3 year survival for 
transplants performed between 2010-14)[20].  
The secondary goal of this immunosuppression approach is to use the three maintenance 
immunosuppression medications in lower dosages in order to minimize toxicity. Tacrolimus 
and sirolimus are both associated with nephrotoxicity. This is particularly problematic in this 
patient population because, as mentioned above, although the renal function is not impaired 
enough to qualify for a renal allograft, the pancreas transplant alone patient population 
frequently present with some degree of renal impairment from the years of diabetes prior to 
transplantation. This regimen permits some reduction in dosage and target trough levels in 
order to minimize post-transplant renal impairment. Additionally, gastroparesis and diabetes 
related bowel dysmotility tends to be more common and more severe in this particular 
recipient population. Mycophenolate mofetil is potentially poorly tolerated in this 
circumstance given its gastrointestinal toxicity which can cause nausea, vomiting or diarrhea. 
This regimen permits lower dosage, as we would usually use twice the dosage in combination 
with tacrolimus alone. This is but one aspect of a post-transplant gastrointestinal protocol that 
we have applied for all of our pancreas transplant recipients which includes early introduction 
of oral intake, narcotic minimization with transversus abdominus plane catheters or injection 
in this plane with liposomal bupivacaine, routine administration of scheduled intravenous 
metoclopramide and subcutaneous methylnaltrexone. Despite all of these interventions, 
readmission most commonly occur for dysmotility and dehydration. 
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In terms of the contribution of rituximab to outcome, it appears that the impact was minimal 
if any. Episodes of acute rejection and short and longterm patient and allograft survivals were 
similar. We have, however, previously published a study reviewing development of donor 
specific antibody  (DSA) after pancreas transplantation in which we demonstrated that 26% 
(9/35) of recipients analyzed developed DSA, but none of the 13 PTA recipients on this 
regimen developed DSA[14]. This was achieved without an increase in infection rate, 
particularly without increasing the rate of CMV infection. This may prove to be a safe and 
potentially effective approach, but a larger series would be required to demonstrate a 
significant improvement in allograft survival. 
Conclusion: Rabbit antithymocyte globulin induction and steroid withdrawal followed by a 
steroid-free three drug immunosuppression regimen is an excellent strategy for pancreas 
transplant alone recipients. Rituximab as a component of induction was well tolerated, though 
a larger patient population with longer follow-up and specific monitoring for development of 
donor specific antibodies and autoantibodies would be required to determine the full impact. 
Acknowledgments: This work was presented at the International Pancreas and Islet 
Transplantation Association (IPITA-IXA-CTS Joint Congress) meeting in Melbourne, 
Australia in 2015. 
Disclosure: The authors of this manuscript have no conflicts of interest to disclose as 
described by the American Journal of Transplantation.  
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
 
  
Table 1. Recipient and donor demographic data for 166 consecutive adult pancreas transplant alone patients
receiving rabbit antithymocyte globulin-based induction therapy (rATG) at Indiana University from 2004 to 2017.
Immunosuppression induction protocol
Antithymocyte globulin Antithymocyte globulin
ALL PTA + Rituximab p-value
TOTAL 166 35 (21%) 131 (79%)
RECIPIENT -
Age (years, median (SD)) 40 (11) 40 (11) 40 (11) 0.76
Gender male 46% 51% 45% 0.50
Race White 92% 91% 92% 0.59
Body mass index (median (SD)) 26.6 (4.3) 24.9 (4.5) 26.8 (4.2) 0.38
Weight at transplant (kg, median (SD) 74.8 (15) 69.4 (16) 75.6 (15) 0.18
Retransplant 6% 9% 5% 0.11
Follow-up months (median (SD)) 80 (45) 141 (32) 62 (35) <0.001
CMV: positive to negative 31% 26% 33% 0.15
Gastroparesis 20% 20% 20% 0.98
DONOR -
Age (years, median (SD)) 23 (10) 24 (10) 23 (11) 0.79
Gender (male) 65% 80% 61% 0.04
Race White 73% 80% 71% 0.11
Body mass index (median (SD)) 24.1 (5.4) 23.7 (4.2) 25.0 (5.8) 0.27
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Table 2. Pancreas transplant clinical outcomes for 166 consecutive adult pancreas transplant alone (PTA)
patients receiving rATG-based induction immunosuppression at Indiana University between 2004 and 2017.
Immunosuppression induction protocol
Antithymocyte globulin Antithymocyte globulin
All PTA + Rituximab p-value
Number 166 35 (21%) 131 (79%)
Graft loss within 7 days 6 (4%) 2 (6%) 4 (3%) 0.37*
Graft loss within 90 days 8 (5%) 2 (6%) 6 (5%) 0.78
Length of hospital stay (days, median (SD)) 7 7 7 0.99
3-month readmission (any) 49% 49% 50% 0.91
For dismotility / dehydration 29% 40% 26% 0.29
1-year post transplant
     Graft survival 91% 86% 92% 0.22
     Patient survival 97% 97% 97% 0.72*
     Rejection (any) 7% 6% 7% 1.00*
     Infection (any) 43% 51% 41% 0.24
Infections
          Cytomegalovirus 11% 9% 12% 0.65
          Bacterial (any) 36% 44% 33% 0.24
          Fungal 4% 0% 5% 0.34*
          Clostridium difficile 9% 12% 9% 0.55
          BK virus 2% 0% 2% 1.00*
Graft function
     HbA1c (median (SD)) 5.5 (0.6) 5.4 (0.6) 5.5 (0.9) 0.15
     C-peptide (median (SD)) 2.0 (1.6) 2.0 (1.7) 2.0 (1.6) 0.61
Patient weight change from baseline (kg) -2.8 (12.0) -3.9 (9.6) -1.3 (12.6) 0.87
Glomerular filtration rate
     Baseline (median (SD)) 90 (12) 90 (12) 90 (12) 0.96
     1-year post transplant (median (SD)) 79 (34) 84 (37) 76 (33) 0.07
* By Fisher's Exact test
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Figure Legends: 
Figure 1a. Cox regression pancreas transplant allograft survival following pancreas transplant 
alone comparing standard immunosuppression induction with and without rituximab. Figure 
1b. Cox regression pancreas transplant allograft death censored survival following pancreas 
transplant alone comparing standard immunosuppression induction with and without 
rituximab. 
Figure 2. Cox regression pancreas transplant patient survival following pancreas transplant 
alone comparing standard immunosuppression induction with and without rituximab. 
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Figure 2 
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